Per Persson,CEO, Acarix, presents at the VIRTUAL, Life Science Day on November 26, a meeting with a primarily focus on in-depth interviews and debates. Expect hard-hitting questions and profound discussions surrounding the invited companies and their respective fields.
The invited companies will present their business and their visions to, later on, open up for debate and questions from our analysts and experts. The format also allows viewers to ask questions to the panel.
Our aim is to provide you with an experience that is as interactive as possible!
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, email@example.com) is Certified Advisor of Acarix.